Wuhan Hiteck Biological Pharma Co., Ltd. Class A

Wuhan Hiteck Biological Pharma Co., Ltd. Class A

SSZSE:300683
21.36
CNY
-0.79
(-3.57%)
-1.50EPS
3.34BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.55
7.94
8.89
9.97
8.69
5.71
6
5.03
5.78
5.4
4.64
4.96
4.14
3.33
Basic EPS, GAAP
1.21
1.59
1.09
2.03
1.65
0.91
0.61
-0.24
0.26
-0.11
-0.93
-0.53
-1.77
-1.48
Free Cash Flow per Basic Share
- -
1.73
1.91
1.57
0.7
0.34
-0.51
-1.28
-2.21
-0.95
-1.25
-0.16
-0.97
- -
Dividend per Share
0.02
- -
0.61
0.79
- -
0.3
0.2
0.16
- -
0.01
0.02
0.01
0.14
- -
Book Value per Share
3.33
7.04
7.69
8.99
15.83
16.54
16.95
16.53
19.04
18.92
18.93
18.27
16.51
15.6
Tangible Book Value per Share
3.06
6.77
7.44
8.75
15.66
13.24
13.67
12.55
15.71
15.7
14.64
14.13
13.2
12.45
Basic Weighted Avg Shares
64
69
76
77
86
103
103
104
106
128
130
131
131
130
Sales/Revenue/Turnover
356
549
679
771
750
591
620
524
615
689
602
649
541
433
Operating Margin (%)
26.62
22.95
22.69
22.68
22.76
19.75
8.79
-3.09
1.37
-0.68
-17.66
-10.47
-22.49
-36.56
Depreciation Expense
- -
6
7
7
9
14
23
29
38
53
71
92
97
- -
Net Income, GAAP
78
110
83
157
142
94
63
-25
28
-14
-121
-69
-231
-192
Effective Tax Rate (%)
14.46
15.19
14.43
14.86
14.86
12.94
15.73
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
21.81
20.03
12.27
20.37
18.98
15.93
10.16
-4.77
4.5
-2.04
-20.06
-10.69
-42.71
-44.41
Working Capital
180
452
485
570
1,493
1,127
1,083
959
1,333
1,159
1,142
943
921
924
LT Debt
- -
- -
- -
2
2
2
2
5
52
44
37
17
4
3
Total Equity
255
537
597
703
1,643
1,720
1,760
1,725
2,343
2,335
2,496
2,412
2,169
2,049
Return on Invested Capital (%)
- -
27.36
14.31
23.74
11.29
5.43
3.63
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
28.02
14.73
23.22
11.62
5.76
3.72
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
27.91
14.74
24.3
12.21
5.63
3.64
-1.45
1.37
-0.61
-5.05
-2.85
-10.16
-8.76

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
52
51
31
LT Borrowings
- -
- -
- -
LT Finance Leases
4
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
131
131
131
Market Capitalization
5,676
3,274
3,343

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,238
1,231
1,193
Cash, Cash Equivalents & STI
424
395
369
Accounts Receivable, Net
67
66
76
Inventories
79
85
84
Total Current Liabilities
297
282
269
Payables & Accruals
- -
- -
- -
ST Debt
52
51
31
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.54%
5.79%
-10.04%
Free Cash Flow
28.59%
99.49%
523.09%
Net Income, GAAP
46.33%
118.17%
233.48%
Sales/Revenue/Turnover
-1.3%
1.59%
-16.57%
Total Cash Common Dividend
- -
583.84%
914.58%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
132
153
166
198
649
2025
157
118
- -
120
541
2026
159
66
88
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.13
-0.05
-0.13
-0.23
-0.53
2025
-0.11
-0.19
- -
-0.56
-1.77
2026
-0.18
-0.43
-0.31
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
0.14
- -
- -
- -
0.14
2026
- -
- -
- -
- -
- -

Company Description

CEO
Ya Chen
Full Time Employees
958
Sector
Health technology
Industry
Biotechnology
Address
Hite Science and Technology Park Wuhan HB China 430056
IPO Date
Aug 8, 2017
Business
Wuhan Hiteck Biological Pharma Co.,Ltd operates as a biopharmaceutical enterprise, dedicated to the innovation, production, and distribution of a diverse portfolio of pharmaceutical products and services across China. The company's core offerings encompass a range of bioengineered preparations and lyophilized injectable medications, including therapies like Jinlujie, a mouse nerve growth factor for injection, alongside chemical drugs such as omeprazole sodium for injection, cyclic adenosine phosphate, and specialized formulations like Xinye acyclovir dispensable tablets. Their product lineup further extends to targeted treatments like Bingbing Horse & Dragon indomethacin furazolidone suppositories, Xunkeyuan tinidazole suppositories, and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck Biological Pharma also delivers essential diagnostic reagents, including kits for detecting measles and rubella virus nucleic acid, mycoplasma isolation and identification kits, and rapid bacterial vaginosis and coronavirus N-protein detection solutions. The firm also provides active pharmaceutical ingredients (APIs), such as Lopinavir and Ritonavir, in addition to pharmaceutical intermediates. Furthermore, it supports the broader pharmaceutical industry with contract research, manufacturing, and development services for both finished preparations and active pharmaceutical ingredients. The company primarily focuses on the nervous system and oncology therapeutic areas. Established in 1992, Wuhan Hiteck Biological Pharma is headquartered in Wuhan, China, and was publicly listed on the Shenzhen Stock Exchange GEM in 2017. In late 2025, the company announced its intention to pursue a Hong Kong listing.